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Abstract
To establish latent infections in B-cells, gammaherpesviruses express proteins in the infected B-cells of the host that
spuriously activate signalling pathways located downstream of the B-cell receptor. One such protein is M2, a murine
gammaherpesvirus 68-encoded molecule that activates the Vav1/Rac1 pathway via the formation of trimolecular complexes
with Scr family members. Previous reports have shown that the formation of this heteromolecular complex involves
interactions between a proline rich region of M2 and the Vav1 and Fyn SH3 domains. Here, we show that the optimal
association of these proteins requires a second structural motif encompassing two tyrosine residues (Tyr120 and 129). These
residues are inducibly phosphorylated by Fyn in non-hematopoietic cells and constitutively phosphorylated in B-cells. We
also demonstrate that the phosphorylation of Tyr120 creates specific docking sites for the SH2 domains of both Vav1 and
Fyn, a condition sine qua non for the optimal association of these two signalling proteins in vivo. Interestingly, signaling
experiments indicate that the expression of M2 in B-cells promotes the tyrosine phosphorylation of Vav1 and additional
signaling proteins, a biological process that requires the integrity of both the M2 phosphotyrosine and proline rich region
motifs. By infecting mice with viruses mutated in the m2 locus, we show that the integrity of each of these two M2 docking
motifs is essential for the early steps of murine gammaherpesvirus-68 latency. Taken together, these results indicate that the
M2 phosphotyrosine motif and the previously described M2 proline rich region work in a concerted manner to manipulate
the signaling machinery of the host B-cell.
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Introduction
Gammaherpesviruses are amongst the most prevalent of human
pathogens owing to their ability to establish lifelong persistent
infections within their hosts [1]. Persistence is achieved through
the establishment of latent infection in conventional memory B
lymphocytes. To gain access to this cell type, gammaherpesviruses
have developed molecular mechanisms that promote B cell
activation in the absence of cognate antigen recognition [2].
Thus, host colonisation by gammaherpesvirus involves the
modulation of signalling pathways triggered upon B cell receptor
(BCR) activation. This strategy offers an obvious advantage to the
virus since infection is not dependent on rare encounters with
antigen specific naive B cells. In addition, virus driven proliferation
of germinal centre (GC) B cells facilitates the amplification of viral
episomes and the subsequent generation of a large pool of latent
genomes in long lived memory B cells [3]. Signalling from the
BCR complex is initiated when Src family kinases such as Fyn, Blk
and Lyn induce the phosphorylation of immunoreceptor tyrosine-
based activation motifs (ITAMs) located in the Iga and Igb
cytoplasmic tails. Tyrosine-phosphorylated ITAMs then recruit
the cytoplasmic Syk protein tyrosine kinase, leading to its
membrane translocation and the subsequent trans-phosphoryla-
tion of important B-cell signalling proteins such as Vav1, Vav2,
phospholipase C-c2 (PLC-c2) and phosphatidylinositol-3 kinase
(PI3K). In turn, these molecules promote the generation of a wide
spectrum of intracellular signals and biological responses that are
essential for the antigenic responses of B lymphocytes [4].
Several gammaherpesvirus proteins have been shown to
modulate signal transduction pathways paralleled to those
activated by BCR recognition of cognate antigen [2]. One such
protein is latent membrane protein (LMP) 2A encoded by Epstein-
Barr virus. This transmembrane protein contains two ITAM-like
sequences that, upon phosphorylation, can interact with Lyn [5].
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Functionally, LMP2A has been shown to drive B cell development
in vivo [6], thus mimicking the presence of a functional BCR [7].
Another example is provided by the Kaposi’s sarcoma-associated
herpesvirus (KSHV) K1 protein. This transmembrane protein also
contains a functional ITAM that mediates interactions with a large
cohort of signalling proteins, including Syk, Lyn, Vav1, PLC-c2
and PI3K [8–11]. Although many studies have addressed the
function of these proteins [12], due to the restricted host range
tropism of the human gammaherpesviruses, their role in vivo has
not been fully demonstrated. Therefore, we still lack studies that
can correlate the biochemical and biological properties of these
viral proteins with the different biological aspects involved in the
pathogenesis of those viruses in their host cells.
A suitable model to circumvent this problem is the use of
murine gammaherpesvirus 68 (MHV-68), because this pathogen
can infect laboratory mice [13,14]. Despite this difference in
tropism, MHV-68 can establish long term latent infection in
memory B cells upon amplification of viral episomes in GC B cells
[15–19]. During the establishment of latency by MHV-68 a
selective number of viral-encoded proteins are expressed that are
predicted to orchestrate biological programs in the host B cell [20].
One of these proteins is M2, a 192 amino acid-long polypeptide
that bears no sequence similarity to any other known protein [21].
One of the functions of M2 is to induce the phosphorylation and
activation of Vav1 and Vav2 in a BCR-independent, but Src
family-dependent manner [22]. Vav1 and Vav2 work as
phosphorylation-dependent guanosine nucleotide exchange factors
(GEFs) for members of the Rho/Rac family [23], a group of
GTPases involved in the regulation of cytoskeletal, mitogenic, and
antigenic responses [24]. The activation of Vav proteins by M2
requires the formation of a trimeric complex between these two
proteins and the tyrosine kinase Fyn [22], a process mediated by
the recognition of a M2 proline rich region (PRR) by the SH3
domains of both Vav and Fyn proteins [22]. Interestingly, we have
previously shown that the formation of this complex results also in
the phosphorylation of M2 on a region that contains two tyrosine
residues (Tyr 120 and Tyr 129) [22]. These results suggested that
in addition to protein interaction events, the function of M2 could
be modulated by phosphorylation-based signals. However, they
could not exclude the possibility that this phosphorylation was a
bystander defect derived from the close physical proximity of M2
and Fyn in the heteromolecular complex.
To investigate the possible implication of phosphorylation-
dependent effects in the functional cycle of M2, we performed in
this work experiments aimed at identifying the specific residues
that were phosphorylated by Fyn on M2. In addition, we
investigated the functional capabilities of M2 mutant proteins
lacking different combinations of these two putative phosphory-
lation sites at the biochemical and signalling level. To obtain
additional information about the regulatory properties of M2 in
vivo, we also compared the pathogenicity of M2 mutant viruses
with disrupted phosphorylation sites, with wild type MHV-68 and
with recombinant viruses bearing previously reported inactive M2
mutant proteins, such as an M2 frame shift mutant [17] and a
PRR-mutant version that cannot trigger the stimulation of the
Fyn/Vav1/Rac1 pathway [22]. Interestingly, these experiments
demonstrated that the phosphorylation of M2 on the tyrosine 120
is critical for the optimal assembly of the M2/Fyn/Vav1 complex
and, perhaps more importantly, for the activation of the latency
program of MHV-68 in infected mice. They also provided
evidence suggesting that the action of M2 in that pathogenic
program involves the manipulation of additional signalling
molecules within B-cells. Taken together, these results reveal
additional mechanistic aspects of the cross-talk established among
M2 and elements of the B-cell signaling machinery that are crucial
for the orchestration of specific biological programs linked to
gammaherpesvirus latency in the host B-cell.
Results
Phosphorylation of M2 on Tyr120 is required for Vav1
activation
We have previously shown that a M2 mutant protein (M2Y)
containing two missense mutations on tyrosine residues 120 and 129
(the amino acid residue positions used in this study for M2 refer to
the final spliced form of this protein, [25]) could not be
phosphorylated by Fyn in vivo or in vitro [22], indicating that these
residues were the actual Fyn targets in M2. To identify the exact
acceptor site of the phosphate group, we generated two M2 mutant
proteins in which either the Y120 (M2Y120F mutant) or the Y129
(M2Y129F mutant) residues were mutated to phenylalanine. To
monitor the phosphorylation of these mutants, these proteins were
expressed in COS1 cells in the presence of Myc-tagged Fyn,
immunoprecipitated, and subjected to immunoblot analysis with
anti-phosphotyrosine (PTyr) antibodies. As a control, we used COS1
expressing either the wild type or the previously described M2Y
mutant version of M2 [22]. These experiments revealed a graded
effect of the mutations in the total levels of M2 phosphorylation.
Thus, the M2Y129F mutant displayed only marginal defects on
tyrosine phosphorylation when compared to its wild type counter-
part (Fig. 1A, upper panel), indicating that this site is not the main
target of Fyn. In contrast, the phosphorylation of M2 was drastically
reduced and totally abolished in the case of the M2Y120F and the
M2Y mutant versions, respectively (Fig. 1A, upper panel). These
results indicate that the main phosphorylation site of M2 is Tyr120.
To investigate the effect of the Y to F mutations in the function
of M2, we used the above anti-M2 immunoprecipitates to monitor
the association of this protein with Fyn. Using anti-Myc
immunoblots, we observed that Fyn could co-immunoprecipitate
at similar levels with both wild type M2 and the M2Y129F mutant
protein. In contrast, its association with M2 was severely reduced
in the case of the M2Y120F mutant and totally abolished when co-
expressed with the M2Y mutant (Fig. 1A, second panel from top).
As previously described [22], Fyn was also tyrosine phosphorylated
in this complex as demonstrated by the detection of phospho-Fyn
in the anti-M2 immunoprecipitates derived from cells expressing
either the wild type or the M2Y129F versions (Fig. 1A, upper
panel). These results suggest that Y120 is involved in the physical
interaction of M2 with Fyn in vivo.
We examined next the role of these two M2 phosphorylation
sites in the coassembly of Fyn and Vav1 and the subsequent
phosphorylation of Vav1. To this end, we co-transfected COS1
cells with Vav1, Fyn and wild type M2 or M2 tyrosine mutants in
the indicated combinations, and examined Vav1 immunoprecip-
itates for the presence of Fyn and M2 proteins (Fig. 1B). While
wild type M2 and the M2Y129F mutant co-immunoprecipitated
equally well with Vav1, the interaction of both M2Y and
M2Y120F mutants with this GEF was significantly reduced
although, unlike the case of the interaction of Fyn with M2Y,
not completely abolished (Fig. 1B, top panel). Likewise, Vav1
associated optimally with Fyn when co-expressed with either wild
type M2 or the M2Y129F mutant. Instead, this complex was
partially or totally lost when M2 was replaced by the M2Y120F
and M2Y mutants in the transfections, respectively (Fig. 1B,
second panel from top). In agreement with these results, in vitro
kinase assays indicated that the optimal phosphorylation of Vav1
by Fyn could be only triggered by wild type M2 and M2Y129F
proteins but not by the rest of Y to F M2 mutants used in the study
(Fig. 1C). Taken together, our results indicate that Y120 is the
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primary phosphorylation residue involved in the formation of the
M2/Vav1/Fyn complex and in Vav1 phosphorylation.
Constitutive phosphorylation of M2 in B cells
In order to address the role of M2 phosphorylation in a more
physiological context, we next monitored the coassembly with Fyn
and Vav1 and the phosphorylation of M2 in A20 cells, a mouse B
cell lymphoma line expressing surface IgGs. To this end, M2 and its
phosphotyrosine mutants were ectopically expressed in these cells.
For comparative purposes, we also analyzed in these experiments the
binding properties and phosphorylation of M2P2, a previously
described M2 mutant protein that lacks the PRR involved in the
recognition of both Vav1 and Fyn [22]. The formation of
heteromolecular complexes was assessed by immunoblot analysis
of Fyn immunoprecipitates for the presence of Vav1 and M2
proteins. These results indicated that Y120 is the primary
phosphorylation residue involved in the formation of the M2/
Vav1/Fyn complex in B cells (Fig. 2A). Next, we examined the
phosphorylation levels of M2 proteins by anti-PTyr immunobloting
of M2 immunoprecipitates. Under these conditions, we observed
that wild type M2 was constitutively phosphorylated on tyrosine
residues even in the absence of BCR stimulation (Fig. 2B, upper
panel; data not shown). This constitutive phosphorylation could be
due to the relatively high basal levels of activation of this cell line
[26]. This phosphorylation was maintained upon mutation of the
Y129 residue but abolished in the case of the replacement of the
Y120 M2 residue (Fig. 2B, upper panel). As expected [22], the
elimination of the proline rich region eliminated the phosphorylation
of M2, as assessed by the lack of detectable phosphorylation levels in
the M2P2 mutant protein (Fig. 2B, upper panel). These results
indicate that the main phosphorylation site of M2 is Y120
independently of the cell type used. To analyze the impact of these
mutations in the activation of Vav1 in B-cells, we monitored by
immunoblot analysis the levels of phosphorylation of endogenous
Vav1 on tyrosine 174 in the transfected A20 cells. Phosphorylation of
this Vav1 site is a good reflection of its activation status, since it has
been shown before that this posttranslational modification induces a
conformational change in the Vav1 molecule that stimulates its
GDP/GTP exchange activity towards Rho/Rac proteins [27–29].
Furthermore, it has been previously shown that M2 induces Vav1
phosphorylation on this site and the concomitant activation of the
downstream Rac1 GTPase [22]. As shown in Fig. 2B, the
phosphorylation of Vav1 induced by the overexpression of M2 in
B-cells did not occur in the case of M2Y120F-transfected cells. As
previously described, Vav1 phosphorylation was also impaired when
theM2P2mutant protein was expressed in A20 cells. In contrast, the
Y129F mutation did not affect the phosphorylation of the
endogenous Vav1 protein at the Y174 position (Fig. 2B).
To verify whether M2 could affect other intracellular proteins in
addition to Vav1, we analyzed total cell extracts from A20 cells by
anti-PTyr immunoblot to monitor the possible phosphorylation of
other B-cell proteins on tyrosine residues upon overexpression of
M2 and the indicated mutants. We observed that M2 and the
M2Y129F mutant induced the phosphorylation of several proteins
of approximately 52, 54, 56, 75, 95 (likely Vav1 itself) and
150 kDa (Fig. 2B, fifth panel from top). Interestingly, the
phosphorylation of these proteins was not observed in A20 cells
expressing either M2Y and/or M2P2 and significantly reduced in
the case of cells expressing the M2Y120F mutations (Fig. 2, fifth
panel from top). Taken together, these results show that Y120 is
the predominant phosphorylated tyrosine of M2 both in lymphoid
and non-hematopoietic cells. Moreover, they indicate that M2 is
also able to promote the BCR-independent phosphorylation of
Vav1 and an additional subset of cellular proteins. This effect is
totally dependent on the presence of both the Y120 residue and
the PRR of M2.
Figure 1. Y120 is the predominant tyrosine required for the formation of the M2/Vav1/Fyn complex and for M2-dependent
phosphorylation of Vav1. COS1 cells were transiently transfected with plasmids encoding the indicated proteins. (A,B) Cells were lysed and
clarified extracts incubated with either anti-M2 (A) or anti-Vav1 antibodies (B). Immunoprecipitates were analysed by western blot with the indicated
antibodies (right side of panels). Western blot analysis of a representative aliquot of total cell lysates (TCL) confirmed expression of proteins (bottom
panels). (C) Cell lysates were incubated with an anti-Vav1 antibody and the resulting immunoprecipitates subjected to an immunocomplex kinase
assay exactly as described previously [22]. Lower panel is an overexposure showing phosphorylation of M2 and its mutant forms. The position of
molecular weight markers is indicated on the right. 2, without; +, with; a, anti; IP, immunoprecipitation; p, phosphorylated; WB, western blot.
doi:10.1371/journal.pone.0001654.g001
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Phosphorylated M2 binds directly to Vav1 and Fyn SH2
domains
The observation that tyrosine phosphorylation regulates the
binding of Fyn and Vav1 to M2 was quite unexpected, since we had
shown before that the interaction of these proteins was mediated by
the M2 PRR [22]. We surmised that the involvement of the
phosphotyrosine M2 motif in this heteromolecular interaction could
be due to two different causes. On the one hand, it was possible that
tyrosine phosphorylation could induce a conformational change in
M2 that resulted in the exposure of the hidden PRR, thereby
facilitating the interaction of this second motif with the M2 target
proteins. On the other hand, it was also feasible that the
phosphorylation sites of M2 could serve as additional docking sites
for Vav1 and Fyn via interactions with the SH2 domains of these two
signalling proteins. To verify the former possibility, we assessed the
binding of several M2 mutants containing Y to D mutations at
positions 120 and 129 to Fyn and Vav1. These mutations mimic the
negative charge created by the incorporation of the phosphate group
on the tyrosine residue so, if the hypothesis of the conformational
change were correct, we expected that some of these mutants could
enhance the binding of Fyn and Vav1 to M2. However, we found
that the Y to D mutations induced effects identical to those elicited
by the Y to F missense mutations, indicating that the role of this
phosphorylation site was not due through conformation-dependent
effects (Fig. 3A,B, top panels).
To assess the second possibility, we first tested the hypothesis that
the SH2 domains of Fyn and Vav1 could bind M2 sequences
containing the phosphorylated Y120 residue. To this end, COS1 cell
lysates containing either the wild type or the SH2 mutant versions of
Fyn and Vav1 were subjected to pull-down experiments with
phosphopeptides (pY) containing either the phosphorylated Y120 or
Y129 residues. After binding, the association of Vav1 and Fyn to
these peptides was determined by immunoblot analysis. As a control
for the specificity of the possible interactions, we included parallel
pull-downs in which peptides were dephosphorylated by the YOP
phosphatase prior to the incubation with cell extracts. As shown in
Figure 4A (two top panels), the pY120 peptide, but not the pY129
peptide, could bind to both Fyn and Vav1. However, this interaction
was lost in the case of the SH2 mutants of Fyn and Vav1 (Fig. 4A,
two top panels) or when the dephosphorylated peptide was used in
the experiments (Fig. 4A, two top panels). These results indicate that
pY120 residue can act as an effective docking site for Vav1 and Fyn.
In order to assess if this interaction required other chaperone
proteins, we repeated these experiments using the isolated SH2
domains of Vav1 and Fyn purified from Escherichia coli as glutathione
S-transferase (GST) fusion proteins. As a negative control, we
performed similar pull-down experiments with the non-chimeric
GST protein. We found that the pY120 peptide could bind directly
both SH2 domains, but that the SH2 domain of Fyn bound more
efficiently than that of Vav1 (Fig. 4B). The phosphorylated peptide
failed to bind to GST (Fig. 4B), confirming the specificity of the
interactions. These differences could not be attributed to loading
artefacts, given that equivalent amounts of peptide and input GST
proteins were used in each pull down experiment.
Figure 2. Role of the phosphotyrosine M2 motif in B-lymphocytes. (A) TCLs from A20 cells expressing the indicated proteins were incubated
with anti-Fyn antibodies and subjected to western blot analysis using the indicated antibodies. As control, aliquots of the same TCLs were analyzed
with anti-Vav1 and anti-Myc antibodies to reveal the levels of endogenous Vav1 and ectopic M2 proteins present in these lysates. (B) M2-transfected
A20 cells were lysed and TCLs analyzed either by immunoprecipitation with anti-M2 antibodies followed by immunoblot with the indicated
antibodies (two upper panels) or by direct immunoblot with the indicated antibodies (rest of panels). The mobility of M2, Fyn and Vav1 proteins is
indicated by arrowheads. The mobility of M2-dependent phosphorylated cellular proteins is indicated by arrows (fifth panel from top). a, anti; IP,
immunoprecipitation; p, phosphorylated; WB, western blot.
doi:10.1371/journal.pone.0001654.g002
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Figure 3. Increased association of Fyn and Vav1 to phosphorylated M2 does not involve phosphorylation-dependent
conformational changes. (A,B) COS1 cells were transiently transfected with plasmids encoding the indicated proteins. After 48 h, cell extracts
were obtained and subjected to immunoprecipitation with either anti-M2 (A) or anti-Vav1 (B) antibodies. Immunoprecipitates were analyzed by
western blot with the indicated antibodies (right side of panels). Aliquots of the TCL used in the immunoprecipitations were analysed in parallel to
confirm expression of the appropriate proteins (bottom panel). 2, without; +, with; a, anti; IP, immunoprecipitation; WB, western blot.
doi:10.1371/journal.pone.0001654.g003
Figure 4. Phosphorylated M2 binds directly to SH2 domains of Fyn and Vav1. (A) COS1 cells were transiently transfected with plasmids
encoding the indicated proteins (top). Cell extracts were incubated with biotinylated peptides containing M2 sequences encompassing
phosphorylated (2) and YOP-mediated (+) dephosphorylated versions of residues 120 and 129. Complexes were recovered with streptavidin-coupled
agarose beads and analyzed by western blot using the indicated antibodies (right side of panels) to reveal the possible association of the indicated
versions of Fyn (top panel) and Vav1 (second panel from top). Western blot analysis of aliquots of TCL confirmed expression of proteins (three bottom
panels). (B) The phosphorylated Y120 peptide described in (A) was incubated with increasing amounts of the indicated GST fusions proteins purified
from bacteria. After binding, the peptide was recovered as indicated above and bound proteins identified by immunoblot analysis using anti-GST
antibodies (upper panel on the left). Aliquots of GST proteins were analyzed by western blotting (upper panel on the right). (C,D) COS1 cells were
transiently transfected with plasmids encoding the indicated proteins. Clarified lysates were incubated with anti-Vav1 (C) or anti-M2 (D) antibodies.
Immunoprecipitates were analyzed by western blotting using the indicated antibodies (left). Aliquots of TCL used in the immunoprecipitations were
analysed in parallel to confirm the expression of proteins used in this experiment (bottom panels). *, point mutation in the indicated domain of Fyn or
Vav1; 2, without; +, with; IP, immunoprecipitation; WB, western blotting.
doi:10.1371/journal.pone.0001654.g004
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To confirm that Vav1 binds to both phosphorylation sites and
the PRR of M2, we next compared the association of M2 with
wild type and mutant Vav1 proteins with inactivated SH2 and the
C-terminal SH3 domains either in the absence or presence of Fyn.
For these experiments, Vav1 N-terminal SH3 mutants were not
analyzed since we have previously shown that M2 only binds to
the C-terminal SH3 domain of Vav1 or Vav2 [22]. In the absence
of Fyn, the inactivation of the C-terminal Vav1 SH3 domain
markedly reduced the M2/Vav1 interaction (Fig. 4C, upper panel,
interaction observed only after longer exposure times, data not
shown), confirming our previous observations [22]. In contrast, the
inactivation of the Vav1 SH2 domain affected only marginally the
association of Vav1 with M2 under these conditions (Fig. 4C,
upper panel). This is consistent with the low phosphorylation levels
of M2 in the absence of Fyn (see above, Fig. 1C, lower panel). As
expected [22], co-expression of Fyn enhanced the interaction
between M2 and Vav1 (Fig. 4C, upper panel). Under these
conditions, a significant level of coimmunoprecipitation was
observed between M2 and SH2 and C-terminal SH3 mutants of
Vav1 (Fig. 4C, upper panel). Therefore, under conditions of
optimal M2 tyrosine phosphorylation, these two domains of Vav1
could efficiently establish physical contacts with the viral protein.
Consistent with previous results [22], we found that Fyn formed
part of the M2/Vav1 complexes (Fig. 4C, second panel from top).
This association could be detected regardless of the Vav1 protein
used (Fig. 4C, second panel from top), indicating that the
association between Vav1 and Fyn is made indirectly via the
scaffolding action of M2. As expected, Fyn also associated with the
phosphorylation sites and the PRR of M2, however, in this case
binding through the SH2 domain had a stronger influence
(Fig.4D, upper panel). Control immunoblots showed equivalent
expression levels of M2, Fyn and Vav1 proteins in the appropriate
samples (Fig. 4C,D). Taken together, these results indicate that
Fyn and Vav1 use two independent docking sites to associate
stably with M2.
The phosphosites and PRR of M2 contribute to the
establishment of latency in GC B cells but they are not
responsible for the full complement of M2 functions
In order to determine the functions of the identified phospho-
sites and the PRR of M2 in physiological context of latency in
vivo, we generated MHV-68 recombinant viruses in which the m2
gene was modified to contain the mutations in either the
phosphorylation motif or the PRR (designated vM2P2, with
proline residues at positions 158, 160, 163 and 167 mutated to
alanine). Given that the Y120F M2 mutant still displayed some
basal phosphorylation in some cell contexts (i.e., COS1 cells), we
decided to use in these experiments a virus encoding the M2Y
mutant (designated vM2Y, with tyrosine residues at positions 120
and 129 mutated to phenylalanine), a version of M2 that shows no
detectable phosphorylation even under conditions of Fyn overex-
pression (see above, Fig. 1A). Moreover, this mutant totally
disrupts the interaction with Fyn and the phosphorylation of B-cell
proteins (see above, Figs. 1A and 2), thus ensuring the total
blockage of the signals emanating from this M2 region. The DNA
structures of mutant viruses were verified by PCR, DNA
sequencing and examination of restriction enzyme digestion
profiles of Escherichia coli-derived BAC DNA and PCR of
reconstituted virus DNA. The stability of the introduced mutations
was further checked in viruses recovered from latently infected
spleens confirming the retention of the engineered point
mutations. Spliced M2 transcripts could be readily detected in
RNA extracted from fibroblasts infected with each of the viruses,
confirming that the mutations did not affect transcription of M2
(data not shown). These viruses were used to infect mice and
analysed for the previously shown functions of M2 in latency. In
addition, we used in this study a previously described M2 frame
shift mutant (vM2FS) that does not express this protein [17]. By
using this additional virus, we wanted to distinguish whether the
phosphosites and the PRR mutants were responsible for either the
totality or just a subset of the functions previously ascribed to M2
during B-cell infection [17,30–32]. To analyse the behaviour of
these viral mutants during latency, we infected Balb/c mice with
each of these viruses and monitored both the establishment and
the long-term latency of MHV-68 in B cells. To this end, we
subjected these animals to three independent, although comple-
mentary biological assays: ex vivo reactivation assays to measure
latent infection in total splenocytes, flow cytometry coupled to
limiting dilution and real time PCR to quantify the frequency of
viral DNA positive GC B cells in spleen, and in situ hybridization
analysis to identify virally infected cells within the spleen. Using
the former assay, we observed in the case of the wild type virus the
expected peak of infection at day 14 post-inoculation, with latent
infection subsiding thereafter to become undetectable at day 50
post-inoculation (Fig. 5) [33]. In contrast, the vM2Y and vM2P2
viruses showed a vM2FS-like pattern of infection during the
establishment of latency. This was characterised by an approxi-
mately 100-fold deficit of latent infection at day 14 post-
inoculation and a subsequent increase in infectious centres by
day 21 post-inoculation when compared with infections made with
wild type viruses (Fig. 5). No preformed infectious virus could be
detected by suspension assay of freeze-thawed spleen homogenates
at any time point and for any virus analyzed, indicating that
splenic infection was only latent. However, unlike the case of the
vM2FS mutant virus, the vM2Y and vM2P2 viruses became
undetectable during long-term latency (Fig. 5). A revertant virus
(vM2Y-R) in which the M2Y locus was restored to wild type status
did not show any defects in the course of infection, indicating that
phenotypic changes observed with the M2Y mutation were
intrinsic to this locus and not the consequence of mutations
elsewhere in the viral genome (Fig. 5). These results indicate that
the PRR and the phosphosites of M2 are responsible for engaging
the cellular responses important for the establishment, but not
maintenance, of latency.
To assess whether the deficit in the establishment of latency
exhibited by the M2 mutant viruses reflected a phenotype in GC B
cells, we determined the frequency of GC B-cells harbouring viral
genomes. In mice infected with vM2Y or vM2P2, the frequency of
viral genome-positive GC B cells only peaked at day 21 post-
infection (Table 1). This was in contrast with the frequencies of
viral genome-positive GC B cells in mice infected with wild type
virus and vM2Y-R, which reached maximal levels at day 14 post-
infection (Table 1). After longer post-infection periods (day 50),
only mice infected with vM2FS exhibited high frequencies of viral
genome-positive B cells (Table 1).
To verify that this infection profile was linked to the residency of
the virus in GC B cells, we monitored the presence of each of those
viruses by detecting transcripts corresponding to the MHV-68-
derived microRNAs using in situ hybridization, an assay that allows
the analysis of the expansion and cessation kinetics of latent
infection within GCs [13,18,34]. Mice infected with either wild
type or vM2Y-R viruses showed the expected pattern of infection
(Fig. 6A,B) [18]. This pattern was characterized by the detection of
large clusters of infected cells within GCs at day 14 post-infection
that reflect cellular proliferation and, thereby, expansion of the
latently infected cell pool (Fig. 6A, panels a,e). At day 21 post-
infection, we observed sharp declines in the total number of
infected GCs and in the number of GCs that were associated with
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the presence of large clusters of latently infected cells. This pattern
reflects the cessation of the virus driven GC B cell proliferation
(Fig. 6A, panels f,j; and Fig. 5B). At later periods (day 50), infection
became confined to a reduced number of cells scattered within
secondary follicles, a phenotype that correlates with the mainte-
nance phase of latent infection (Fig. 6A, panels k,o). The kinetics
and pattern of infection in the spleens of mice inoculated with
vM2FS was as previously reported [17]. Thus, after infection with
this virus, maximal numbers of large clusters of infected GC B cells
were reached only at day 21 post-infection (Fig. 6A, panel g). High
levels of latent infection were still observed at day 50 post-infection
(Fig. 6A, panel l), where almost 100% of the miRNA-positive
follicles presented with large clusters of infected cells (Fig. 6B). In
the case of infections by vM2Y and vM2P2, there was a reduced
number of miRNA positive follicles at day 14 post-infection
(Fig. 6A, panels c,d). This deficit reflected both a decreased
number of infected follicles as well as a low number of positive
follicles with large clusters of latently infected cells when compared
Table 1. Frequency of genome-positive GC B cellsa
Days
p.i. Virus
Reciprocal frequencyb of viral
DNA+ GC B cells (95% CI) %Cellsc
Total no. of
cellsd
No. of viral DNA-
positive cellse
14 WT 3 (2–6) 5.7 1.16107 3,666,667
M2FS 61 (39–142) 5.7 1.16107 180,328
M2Y 23 (15–53) 7.8 1.66107 608,696
M2P2 26 (17–60) 8.9 1.86107 692,308
M2Y-R 6 (4–13) 6.8 1.46107 2,333,333
21 WT 79 (51–175) 6.0 1.26107 151,899
M2FS 6 (4–12) 6.0 1.26107 2,000,000
M2Y 23 (14–58) 4.3 8.66106 373,914
M2P2 10 (7–21) 4.1 8.26106 820,000
M2Y-R 51 (32–119) 4.9 9.86106 192,157
50 WT 148 (92–380) 2.1 4.26106 28,378
M2FS 8 (6–17) 4.9 9.86106 1,225,000
M2Y 128 (77–381) 1.5 3.06106 23,437
M2P2 256 (169–527) 2.6 5.26106 20,233
M2Y-R 78 (52–162) 1.7 3.46106 43,897
aData were obtained from pools of at least five spleens.
bFrequencies were calculated by limiting-dilution analysis with 95% confidence intervals (CI).
cThe percentage of GC B cells from total spleen was estimated by FACS analysis.
dThe total number of cells was estimated from the percentage of the total spleen, based on an estimate of 26108 cells/spleen.
eThe number of latently infected cells was based on the frequency of latency within GB B cells and the estimated total number of cells.
doi:10.1371/journal.pone.0001654.t001
Figure 5. Activation of Vav proteins is necessary to the establishment of normal levels of latency in spleen. Balb/c mice were intranasally
infected with viruses of the indicated viral genotypes and latent load quantified by ex-vivo reactivation. Each point represents the infectious center titre
from an individual mouse. Horizontal bars indicate arithmetic means. The dashed line indicates the limit of detection of the assay.
doi:10.1371/journal.pone.0001654.g005
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to wild type virus (Fig. 6B). In this case, maximal levels of GC
infection were only observed at day 21 post-infection (Fig. 6A,
panels h,i). These levels declined thereafter and reached values
equivalent to those observed in the case of wild type and the
vM2Y-R viruses (Fig. 6A, panels m,n). Taken together, these
results indicate that the PRR and the phosphotyrosine sites of M2
work coordinately during infection in vivo, where they play
essential roles in the M2 functions linked to the establishment of
latency within GC B-cells. Furthermore, they suggest that the
functions of M2 related to latency maintenance are probably due
to other motifs of this molecule, raising the possibility that separate
regions of the M2 molecule regulate different branches of the
pathogenicity program of MHV-68.
Discussion
M2 is a MHV-68 encoded protein that modulates signalling
pathways linked to the establishment of viral latency in B cells. M2
contributes to the latency program through the manipulation of
key signal transduction pathways [22,35]. In order to do so, M2
Figure 6. Modulation of Vav activity is required for normal kinetics of latency in GC B cells. Balb/c mice were intranasally infected with
viruses of the indicated viral genotypes. Spleen sections were processed for in situ hybridization with miRNA riboprobes. (A) Representative spleen
sections from each group of animals. Dark staining indicates cells positive for viral encoded miRNAs. All sections are magnified at6200 and counter
stained with haematoxylin. (B) Mean percentage 6 SEM of miRNA+ follicles (filled bars) and positive follicles with large clusters of miRNA-positive
cells (open bars). Six sections per mouse and at least four mice per group were counted at each time point. Follicles were scored positive if they
contained at least one positive miRNA cell and positive for expansion if they contained more than ten miRNA positive cells.
doi:10.1371/journal.pone.0001654.g006
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utilises different structural motifs present in its primary structure.
For example, it has been shown that the activation of the Vav
pathway requires the interaction of the M2 PRR with the C-
terminal SH3 domains of Vav1 and Vav2 proteins [22]. Likewise,
the M2-dependent down-modulation of the STAT pathway
requires a scattered motif distributed between the central basic
region and N-terminal amino acids of M2 [35,36]. Whether other
regions of M2 contribute to these or other functions remained to
be determined up to now. Here, we show that a tyrosine-
phosphorylated region of M2 constitutes a third M2 regulatory
motif that contributes to the establishment of MHV-68 latency in
B cells. This region contains two tyrosine residues (Tyr120 and
129) that are inducibly phosphorylated in ectopic systems by Fyn
and constitutively phosphorylated in the A20 B-cell line. By using
mutant proteins targeted in these two residues, we have
demonstrated that Tyr120 is the primary phosphorylation site of
M2 while Tyr129 contributes much less to the overall phosphor-
ylation of the protein. Interestingly, we have observed that this
new region and the M2 PRR need to work together in order to
activate optimally the Fyn/Vav1 pathway.
The structural dissection of these two motifs indicates that the
cooperative action of the phosphotyrosine residues and the PRR is
not mediated by major structural changes that expose putative
cryptic binding sites of the M2 molecule. Instead, we have
demonstrated that these two motifs work as independent docking
sites for the SH3 and SH2 domains of both Vav1 and Fyn. In
agreement with this view, we have observed that the optimal
binding of Fyn to M2 requires the presence of both the
phosphotyrosine and PRR motifs. Furthermore, we have also
shown that Vav1 proteins with non-functional C-terminal SH3 or
SH2 domains can still bind to M2, although at much lower levels
than those observed with the wild type protein. Supporting this
dual docking site model, we have also shown that the defective
interaction of the Vav1 SH3 mutant with M2 is rescued by the
overexpression of Fyn and the subsequent phosphorylation of M2.
The requirement of two independent motifs for the optimal
binding of Vav proteins to other partners is not unprecedented.
Thus, previous studies have shown that binding of Vav1 to Cbl-b
requires the SH2 and SH3 regions [37] and, of particular
relevance to the current study, it has been reported that the
binding of Vav2 (and presumably the rest of Vav family proteins)
to mDia/interacting protein requires the simultaneous engage-
ment of a tyrosine phosphorylation motif and a PRR [38].
The study of the signalling properties of M2 and its mutants in
B-cells has revealed that this protein may also use other B-cell
targets. Thus, we have shown that the enforced expression of M2
in A20 cells results in the tyrosine phosphorylation of five
additional proteins whose molecular weights range between 50
and 150 kDa. Consistent with our observations with Vav1 and
Fyn, we have observed that the mutation of M2 in either the
phosphotyrosine motif or the PRR disrupt these phosphorylation
events. Likewise, we have shown that the Y120 phosphorylation
residue has a much relevant biological role than the Y129 site in
this cellular response. These results underscore the concept that
the phosphotyrosine motif and the PRR of M2 exert intertwined
actions for the optimal manipulation of the B-cell signalling
machinery. At this moment, we do not know whether these
additional M2-dependent phosphoproteins are direct M2 binding
partners or, alternatively, downstream elements activated by either
Fyn or Vav1. Preliminary experiments favour the former
possibility, since we have observed by pull-down experiments that
M2 phosphopeptides can bring down some of those phosphopro-
teins. Thus, it is likely that, as in the case of the KSHV K1 protein
[9,11], M2 could mediate the formation of a complex signalosome
with a subset of B-cell signalling proteins. We are conducting
currently proteomic experiments to identify these new putative M2
targets.
The presence of two interacting motifs in the M2 structure
raises interesting regulatory possibilities. According to the previous
model of interactions of Vav1 and Fyn with the M2 PRR, it was
difficult to understand how the M2/Fyn/Vav1 complex could be
assembled, since Fyn and Vav1 will be binding to the same M2
PRR. The presence of two docking sites involved in this
interaction solves this problem, since it is possible that the trimeric
complex will be formed through the independent binding of Vav1
and Fyn to either the phosphotyrosine motif or the PRR. Given
that both proteins can bind to these two regions of M2, this
trimeric complex may form in different ways. For example, Vav1
could associate with the PRR or the phosphotyrosine motif when
Fyn is bound to the phosphotyrosine or PRR, respectively. In
favour of this hypothesis, we have observed that Fyn can be
detected in an M2-dependent manner in the anti-Vav1 immuno-
precipitates regardless of whether this GEF has inactivating
mutations in either the SH2 (that disrupts its association with
the M2 phosphotyrosine motif) or the C-terminal SH3 domain
(which blocks its association to the M2 PRR). However, we cannot
exclude the possibility that the trimeric complex could be also
formed with those two proteins binding simultaneously to the two
M2 docking sites. This alternative mechanism of assembly is only
feasible if M2 forms homodimers within the host cell. Preliminary
experiments conducted in our lab indicate that this is not the case
(data not shown). An issue that is still problematic according to this
model of interaction is the understanding of how Fyn becomes
associated with M2 in the first place. According to our present
results, Fyn only binds to M2 when both the PRR and the
phosphotyrosine domains are functional. If so, how is this complex
formed when M2 is non-phosphorylated? To solve this signalling
conundrum, we favour a model in which the association of Fyn
and M2 will entail two independent, and mechanistically separable
steps. In the first step, the initial binding of Fyn to M2 would be
triggered by the prior trans-phosphorylation of M2 by Fyn in the
absence of complex formation or, alternatively, by the binding of
Fyn to M2 molecules previously phosphorylated by other protein
tyrosine kinases. This trans-phosphorylation could occur in the
absence of direct physical interactions since the constitutive
localization of M2 in the plasma membrane makes it possible
the presence of other membrane-bound kinases in the neighbour-
hood [22]. This model is mechanistically similar to the binding of
Syk to the tyrosine-phosphorylated sequences of the Iga and Igb
ITAM regions. This initial phosphorylation step would lead to the
subsequent physical interaction of Fyn to either uncomplexed M2
proteins or to the M2/Vav1 complex, a result that would trigger
the subsequent phosphorylation of Vav1 by the associated kinase.
In any case, it is worth mentioning that M2 can be detected in
binary complexes with Vav1 and Fyn alone, indicating that M2
will display different forms of engagement during the establish-
ment of viral latency such as free forms, binary complexes with
either Vav1 or Fyn, and the trimeric M2/Vav1/Fyn complex.
This spectrum of states may be even larger if the additional
phosphoproteins triggered by M2 in B-cells also associate with M2
following Vav1- or Fyn-like mechanisms.
Our results with the Y to F M2 mutants also suggest that the
phosphorylation levels of the wild type M2 protein could be used
to induce different signalling outputs within the host cells. For
instance, we have observed that the phosphorylation pattern
induced by M2 in B-cells follows a gradient response, with a total
absence of signal in the case of the M2Y mutant, a low but
detectable signal elicited by the M2Y120F mutant, and the robust
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phosphorylation of B-cell proteins upon expression of the wild type
M2 protein. These results suggest that if M2 undergoes different
levels of phosphorylation in these two residues during the MHV-
68 infection, this information could be computed by the B-cell to
trigger intracellular signals of different intensity and/or to
stimulate distinct, signal-dependent biological programs. This
possibility would add further plasticity for the regulation of the
MHV-68 pathogenic program in the host cell. In this regard, it will
be interesting to generate phosphospecific antibodies to M2 in the
future to monitor the phosphorylation kinetics of M2 during the
different phases of MHV-68 latency in vivo.
The importance of these two M2 docking motifs for MHV-68
latency is further strengthened by the data derived from the
infection of mice with MHV-68 mutant viruses harbouring
different M2 mutants. This genetic strategy has confirmed in vivo
the important functional role of both the phosphotyrosine and the
PRR motifs for the establishment of MHV-68 latency in B cells.
Moreover, the observation that the phenotypes obtained by the
M2Y and M2P2 proteins are identical, further strengthens the idea
regarding the coordinated action of these two docking motifs
during the function of M2 in the host cell. Interestingly, the use of
this genetic strategy also revealed that the infection of mice with
vM2Y and vM2P2 viruses does not recapitulate the overall
biological program of the M2 protein during MHV-68 latency.
Thus, in contrast to what is observed with a M2 frame shift mutant
virus, we have observed that the infection of animals with those
viruses does not result in the induction of persistent uncontrolled
proliferation of infected GC B cells. These results indicate that
other regions of M2 mediate this latter stage of the MHV-68
pathogenic program. Whether this is due to additional, intrinsic
functions of M2 or to indirect causes, i.e. clearance of the virus by
the immune system, remains to be determined.
Collectively, our present data indicates that M2 functions as a
multidocking protein that promotes the spurious, BCR-indepen-
dent activation of the Vav1/Rac1 pathway and other intracellular
routes. Furthermore, we have demonstrated genetically that the
intracellular effects triggered by the concerted action of the
phosphotyrosine and PRR M2 motifs are essential for the
establishment of MHV-68 latency in GC B-cells but not for the
subsequent maintenance of long term latency, suggesting the
possibility that M2 could trigger distinct signalling branches that
contribute independently to different stages of the MHV-68
pathogenic program. Finally, the observation that M2Y and M2P2
disrupt MHV-68 latency raise the prospect of using phosphopep-
tides and/or PRR-containing peptides to block latency in vivo or,
alternatively, to use in pharmacological approaches to block the
activity of specific signalling pathways in B lymphocyte-based
diseases. Further studies linking the biochemical properties of M2
with the pathogenesis of MHV-68 should provide valuable insights
into the physiological role of this pathway for gammaherpesvirus
host colonization.
Materials and Methods
Plasmids
pCMV-Myc constructs, encoding wild type M2, M2Y and
M2P2 mutants, and pcDNA3-Vav1 expression plasmid encoding
wild type mouse Vav1, have been described previously [22,39].
pCMV-Myc-Fyn, encoding wild type mouse Fyn was generated by
subcloning the Fyn cDNA sequences from the corresponding
pCMV-HA expression construct [22]. pCMV-Myc constructs
encoding Y120F, Y129F, Y120D, Y129D and Y120,129D (2YD)
M2 mutants, and pCDNA3 encoding Vav1 with an inactivating
amino acid substitution (R696A) in the SH2 domain [40] or
encoding Fyn with an inactivating amino acid substitution
(R176K) in the SH2 [41,42] or (W119L) in the SH3 domains
[43], were generated by site directed mutagenesis using a
Stratagene Quickchange kit according to the manufacturer’s
instructions. A pCDNA3 encoding Vav1 with an inactivating
amino acid substitution (P833L) in the most C-terminal SH3
domain has been described [44]. A pGEX-2T construct encoding
the SH2 domain of Vav1 has been described [45]. The sequence
encoding the SH2 domain of mouse Fyn (residues 145–247) was
amplified by PCR and cloned into pGEX-6P-1 expression vector
(GE Healthcare). All constructs were verified by DNA sequencing.
Antibodies and fusion proteins
A rabbit polyclonal antibody to M2 has been described before
[22]. Other antibodies used in this work included phosphospecific
antibodies to Vav1 phospho-Y174 [46], a monoclonal antibody
against the c-Myc epitope (Invitrogen/Clontech), rabbit polyclonal
antibodies to Vav1 and Fyn (Santa Cruz), an anti-phosphotyrosine
monoclonal antibody (PY99, Santa Cruz) and a goat polyclonal
antibody to glutathione S-transferase (GE Healthcare). GST and
GST-SH2 fusion proteins were produced in Escherichia coli by
IPTG (isopropyl-B-D-thiogalactopyranoside) induction and puri-
fied with glutathione-sepharose beads using standard procedures.
Cells and transfections
COS1 and NIH3T3 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat inactivat-
ed foetal bovine serum, 2 mM glutamine and 100 U/ml penicillin
and streptamicin. Baby hamster kidney cells (BHK-21) were
cultured in Glasgow’s modified Eagle’s medium supplemented as
described above plus 10% tryptose phosphate broth. For
immunoprecipitation and pull down assays, COS1 cells were
transfected with 2–4 mg of the indicated plasmids using the DEAE-
dextran method. A20 B cells were propagated in RPMI 1640
medium supplemented with 10% heat inactivated foetal bovine
serum, 2 mM glutamine and 100 U/ml penicillin and streptami-
cin. For transfection, 26107 A20 cells were electroporated (270 V,
500 mF) with 15 mg of plasmid DNA using a Bio-Rad gene pulser
and incubated for 24 h in supplemented RPMI.
Immunoprecipitation and in vitro kinase assays
Transfected COS1 or A20 B cells were rinsed twice in ice-cold
PBS and disrupted with ice-cold lysis buffer containing 10 mM
Tris-HCl pH7.4, 100 mM NaCl, 1mM NaF, 1 mM orthovana-
date, 0.5% NP-40 and Cwmplete protease inhibitors. Lysates were
clarified by centrifugation and incubated with 1 mg of antibodies
to either M2 or Vav1 or Fyn for 2 h at 4uC. A20 B cell lysates
were precleared with protein-G conjugated Sepharose beads (GE
Healthcare), prior to incubation with anti-M2 serum. Immune-
complexes were recovered by incubation with protein G-
conjugated Sepharose beads for 45 min at 4uC. After 3 washes
with ice-cold lysis buffer, proteins were eluted in reducing
Laemmli’s buffer, resolved by SDS-PAGE, transferred to nitro-
cellulose and immunoblotted with the indicated antibodies. For in
vitro kinase assays, Vav1 immunoprecipitates were obtained as
described above, washed twice in lysis buffer, and then subjected
to an in vitro kinase assay as previously described [22]. Proteins
were eluted in reduced Laemmli’s buffer and resolved by SDS-
PAGE. Gels were fixed, dried and subjected to autoradiography.
Pull-down experiments
N-terminal biotinylated, tyrosine phosphorylated (pY) peptides
corresponding to a region of M2 incorporating Y120 (SPEENI-
pYETANSE) and Y129 (ANSEPVpYIQPIST) were purchased
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from Sigma. A non-phosphorylated version of the Y120 peptide
was obtained by incubation with 50 U of YOP tyrosine phosphatase
(New England Biolabs), for 30 min at 30uC. The enzyme was
inactivated by the addition of 1 mM orthovanadate. For pull-down
experiments, 10 mg of each peptide were incubated with clarified cell
lysates or purifiedGST proteins overnight at 4uC. Peptide complexes
were recovered with 20 ml of streptavidin-conjugated Sepharose
beads (GE Healthcare) for 1 h at 4uC. After 3 washes in lysis buffer,
proteins were eluted from the beads in reducing Laemmli’s buffer,
resolved by SDS-PAGE, transferred to nitrocellulose and analysed
by western blot with the indicated antibodies.
Generation of recombinant viruses
MHV-68 vM2Y (with tyrosine residues at positions 120 and 129
mutated to phenylalanines) and vM2P2 (with proline residues at
positions 158, 160, 163 and 167 mutated to alanines) viruses were
generated by mutagenesis of the viral genome cloned as a bacterial
artificial chromosome (BAC) [47,48]. The following point
mutations were introduced on the M2 gene by overlapping PCR
using MHV-68 genomic DNA as a template: T4221, 4228A in
vM2Y and G4108, 4120, 4129, 4135C in vM2P2. PCR products were
inserted into the HindIII E MHV-68 fragment cloned in the
pST76K-SR shuttle plasmid [17], using BlnI (nt 3908) and XhoI (nt
5361) restriction sites. The PCR-derived regions were sequenced
to confirm the integrity of the mutations. Recombinant HindIII E
shuttle plasmids were transformed into an Escherichia coli strain
(DH10B) containing the wild type MHV-68 BAC (pHA3).
Following a multi-step selection procedure, recombinant BAC
clones were identified by DNA sequencing. To generate a vM2Y
revertant virus (vM2Y-R), the wild type HindIII E pST76K-SR
shuttle plasmid was transformed into DH10B cells containing the
mutant BAC genome. All viruses were reconstituted by transfec-
tion of BAC DNA into BHK-21 cells using FuGENE 6 (Roche
Molecular Biochemicals). The loxP-flanked BAC cassette was
removed by viral passage through NIH Cre 3T3 cells and limiting
dilution to obtain GFP-negative viruses.
Analysis of recombinant viruses
Groups of 6- to 8-week old female BALB/c mice (Instituto
Gulbenkian de Cieˆncia, Portugal) were inoculated intranasally
with 104 p.f.u. in 20 ml of PBS under halothane anaesthesia. At 14,
21 or 50 days post-infection, spleens were removed and processed
for subsequent analysis. Titres of infectious virus were determined
by suspension assays of freeze-thawed spleen homogenates using
BHK-21 cells. Latent virus load was quantified by using explant
cocultures of single-cell suspension splenocytes with BHK-21 cells.
Plates were incubated for four (suspension assays) or five (coculture
assays) days, then fixed with 10% formal saline and counterstained
with toluidine blue. Viral plaques were counted with a microscope.
The frequency of MHV-68 genome-positive GC B cells was
determined by limiting dilution combined with real-time PCR,
essentially as previously described [20]. GC B cells (B220+; PNAhi)
were obtained from pools of five spleens using a BD FACSAria
Flow Cytometer (BD Biosciences). The purity of sorted cells was
always .98%. Real-time PCR was performed on a ABI Prism
7000 Sequence Detection System (Applied Biosystems) according
to the manufacturer’s instructions, using the fluorescent Taqman
methodology. It is important pointing out that the change in the
value range in these experiments when compared with previous
published work using the Light Cycler apparatus from Roche
Molecular Biochemicals, is due to the higher sensitivity of the real-
time PCR methodology performed here. Noteworthy, that this
change in sensitivity affects the total values but not the fold
difference in the frequencies of viral DNA positive cells for wild
type MHV-68 when compared to vM2FS. In fact, if we compare
the fold changes in the present and previous manuscripts, they are
actually very similar (compare current manuscript and [20]).
Primer/probe sets used were specific for the MHV-68 M9 gene (59
primer: GCCACGGTGGCCCTCTA; 39 primer: CAGGCCTC-
CCTCCCTTTG; probe: 6-FAM-CTTCTGTTGATCTTCC–
MGB). Samples were subjected to a melting step of 95uC for
10 min followed by 40 cycles of 15 s at 95uC and 1 min at 60uC.
In situ hybridization with a digoxigenin-labelled riboprobe
encompassing both MHV-68 vtRNAs and microRNAs 1 to 4
was performed on formalin-fixed, paraffin-embedded spleen
sections, as previously described [49]. Probes were generated
by T7 transcription of a pEH1.4 using a commercial kit from
Roche Molecular Biochemicals, according to the manufacturer’s
instructions.
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